REG - Oncimmune Hldngs PLC - Block Listing Six Monthly Return

Oncimmune HoldingsAnnouncement

06/04/2021 13:50

RNS Number : 5398U
  
Oncimmune Holdings PLC
  
06 April 2021
  
 

6 April 2021
 
 
Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
Block Listing Six Monthly Return
 
 
Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").
 



Name of applicant:


Oncimmune Holdings plc
 




Name of scheme:


Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans
 




Period of return:


15 September 2020 to 15 March 2021
 




Balance of unallotted securities under scheme(s) from previous return:
 


 5,998,772




Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
 


0




Less: Number of securities issued/allotted under scheme(s) during period:
 


 168,618




Equals: Balance under scheme(s) not yet issued/allotted at end of period:
 


 5,830,154



 
 
For further information:
 
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
contact@oncimmune.co.uk
 
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
 
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
 
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
 
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BLRSSWFEMEFSELL